Study on the effectiveness of sodium thiosulfate in preventing cisplatin induced ototoxicity in patients with moderate risk neuroblastoma and its impact on prognosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082442

Enrollment

Unknown

Registered

2024-03-29

Start date

2022-10-19

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neruoblastoma

Interventions

GROUP A intervention:Sodium thiosulfate 10kg,20g/m2

Group B control group:no STS

Eligibility

Sex/Gender

Male

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Untreated children with primary intermediate risk neuroblastoma, less than or equal to 18 years old.

Exclusion criteria

Exclusion criteria: 1. Children with neuroblastoma who have been treated in other hospitals; 2. Patients with estimated survival time less than 1 week; 3. At the time of enrollment, the children had obviously abnormal hearing.

Design outcomes

Primary

Measure	Time frame
Hearing impairment - Boston classification;Event Free Survival;	—

Countries

China

Contacts

Public ContactGao Yijin

Shanghai Children's Medical Center Affiliated to Medical College of Shanghai Jiaotong University

gaoyijin@scmc.com.cn+86 138 1611 6777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026